ArticleCureus2024
Significance of Misoprostol-Induced Cervical Ripening Prior to Hysteroscopy.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Hysteroscopy, a minimally invasive procedure for diagnosing and treating intrauterine pathologies, can be challenging due to inadequate cervical dilation, leading to procedural difficulties and patient discomfort. Misoprostol, a synthetic prostaglandin E1 analog, is increasingly used for cervical ripening to ease hysteroscopic procedures. Objective To evaluate the efficacy and safety of misoprostol for cervical ripening prior to hysteroscopy. Material and methods This prospective study included 539 women who presented to the Gynecology OPD for elective hysteroscopy. Participants were randomly assigned to either Group A (n=300), who received 400 µg misoprostol vaginally at night before hysteroscopy, or Group B (n=239), who had a placebo. The outcomes assessed were cervical dilation, procedural time, patient-reported pain during hysteroscopy, and placement of a copper IUD on post-insertion day 1 as defined by the visual analog score (VAS), incidence of cervical lacerations, or adverse side effects. Results Group A had significantly higher rates of achieving greater cervical dilation compared to Group B. Specifically, 50% of patients in Group A achieved a dilation of 7-8 mm, and 15% achieved dilation greater than 8 mm, whereas only 10% and 5% of patients in Group B achieved these levels of dilation, respectively. The need for additional mechanical dilation was lower in Group A (10% vs. 55%). Procedural times were shorter in Group A, with 75% of procedures taking 10 minutes or less compared to 30% in Group B. Patient-reported pain was also lower in Group A. Conclusion Misoprostol improves cervical ripening before hysteroscopy, reducing the need for mechanical dilation, shortening operation time, and lowering pain levels. Despite moderate side effects, it remains a key preoperative cervical preparation due to its procedural and patient comfort benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.